• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-3MEF filed by ASP Isotopes Inc.

    7/23/25 4:53:34 PM ET
    $ASPI
    Major Chemicals
    Industrials
    Get the next $ASPI alert in real time by email
    S-3MEF 1 aspi_s3mef.htm S-3MEF aspi_s3mef.htm

    As filed with the Securities and Exchange Commission on July 23, 2025

    Registration No. 333-            

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-3

     

    REGISTRATION STATEMENT 

    UNDER

    THE SECURITIES ACT OF 1933

     

    ASP Isotopes Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    87-2618235

    (State or other jurisdiction of

     

    (I.R.S. Employer

    incorporation or organization)

     

    Identification Number)

     

    601 Pennsylvania Avenue NW

    South Building, Suite 900 

    Washington, D.C. 20004

    (202) 756-2245

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Paul E. Mann 

    Executive Chairman and Chief Executive Officer

    ASP Isotopes Inc.

    601 Pennsylvania Avenue NW

    South Building, Suite 900

    Washington, D.C. 20004

    (202) 756-2245

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copy to:

    Donald G. Ainscow, Esq.

    Blank Rome LLP

    200 Crescent Court, Suite 1000

    Dallas, TX 75201

    Tel: (972) 850-1450

    Fax: (972) 850-1451

     

    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ☒ 333-286860

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐ 

    Non-accelerated filer

    ☒ 

    Smaller reporting company

    ☒ 

     

     

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    This registration statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.

     

     

     

     

    EXPLANATORY NOTE

    AND INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

     

    Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, ASP Isotopes Inc. (the “Registrant”) is filing this Registration Statement on Form S-3 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”). This Registration Statement relates to the public offering of securities contemplated by the Registration Statement on Form S-3 (File No. 333-286860) (the “Prior Registration Statement”), which the Registrant originally filed with the Commission on April 30, 2025, and which the Commission declared effective on May 30, 2025.

     

    The Registrant is filing this Registration Statement for the sole purpose of increasing the aggregate number of securities offered by the Registrant by a proposed aggregate offering price of $10,000,000. The additional securities that are being registered for issuance and sale represent no more than 20% of the maximum aggregate offering price of unsold securities under the Prior Registration Statement. The information set forth in the Prior Registration Statement and all exhibits to the Prior Registration Statement are hereby incorporated by reference into this Registration Statement.  The required opinion and consents are listed on the Exhibit Index below and filed herewith.

     

     
    2

     

     

    PART II

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16. Exhibits.

     

    (a) Exhibit Index

     

    All exhibits filed with or incorporated by reference in the Prior Registration Statement are incorporated by reference into, and shall be deemed a part of, this Registration Statement, and the following additional exhibits are filed or incorporated by reference herewith, as part of this Registration Statement:

     

    Exhibit Number

     

    Description 

     

     

    5.1

     

    Opinion of Blank Rome LLP.

    23.1

     

    Consent of Independent Registered Public Accounting Firm.

    23.2

     

    Consent of BDO South Africa Incorporated

    23.3

     

    Consent of Blank Rome LLP (included in Exhibit 5.1).

    24.1

     

    Power of Attorney (incorporated by reference to Exhibit 24.1 to the Prior Registration Statement).

    107

     

    Filing Fee Table.

     

     
    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Washington, D.C. on July 23, 2025.

     

     

    ASP ISOTOPES INC.

     

     

     

     

     

    By

    /s/ Paul E. Mann

     

     

     

    Paul E. Mann

    Executive Chairman and Chief Executive Officer

     

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Paul E. Mann

     

    Executive Chairman, Chief Executive Officer and Director

    (Principal Executive Officer)

     

    July 23, 2025

    Paul E. Mann

     

     

     

     

     

     

     

    /s/ Heather Kiessling

     

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

     

    July 23, 2025

    Heather Kiessling

     

     

     

     

     

     

     

    *

     

    Director

     

    July 23, 2025

    Michael Gorley, Ph.D.

     

     

     

     

     

     

     

    *

     

    Director

     

    July 23, 2025

    Sipho N. Maseko

     

     

     

     

     

     

     

    *

     

    Director

     

    July 23, 2025

    Duncan Moore, Ph.D.

     

     

     

     

     

     

     

    *

     

    Director

     

    July 23, 2025

    Robert Ryan

     

     

     

     

     

     

     

    *

     

    Director

     

    July 23, 2025

    Todd Wider, M.D.

     

     

     

    * By: 

    /s/ Paul E. Mann

     

    Paul E. Mann

     

     

    Attorney-in-Fact

     

     

     
    4

     

    Get the next $ASPI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASPI

    DatePrice TargetRatingAnalyst
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    10/4/2024$4.50Buy
    Canaccord Genuity
    12/5/2023$3.25Buy
    H.C. Wainwright
    More analyst ratings

    $ASPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Operating Officer Ainscow Robert bought 19,992 shares, increasing direct ownership by 2% to 919,992 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:49 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Chief Executive Officer Mann Paul Elliot bought 39,984 shares, increasing direct ownership by 0.69% to 5,845,627 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/15/24 10:33:33 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Large owner Ak Jensen Investment Management Ltd bought $515,088 worth of shares (161,849 units at $3.18) (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    7/10/24 5:59:47 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    SEC Filings

    View All

    ASP Isotopes Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    1/30/26 5:00:39 PM ET
    $ASPI
    Major Chemicals
    Industrials

    SEC Form SCHEDULE 13G filed by ASP Isotopes Inc.

    SCHEDULE 13G - ASP Isotopes Inc. (0001921865) (Subject)

    1/30/26 1:28:15 PM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    1/29/26 7:30:46 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ASP Isotopes Inc. Provides Production Update on the Renergen Helium Project

    This Production Update reports operational progress since April 2025, following bridge loan funding provided by ASP Isotopes Inc. ("ASPI") (prior to the completion of ASPI's acquisition of Renergen), and highlights measurable improvements in drilling execution, gas production, subsurface confidence, and commercial readiness since ASPI involvement. Key highlights include: Investment has augmented existing operational capacity. Management estimates the plant is now processing approximately 60% more gas as a result of improvements and new production wells tied to the plant.Significant improvement in subsurface capability following the engagement of Kinley Exploration:for the first time on the

    1/29/26 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Closes Acquisition of Renergen

    Combined Company Expected to Become a Global Critical Materials Provider Focused on High-Growth Industries in Isotope and Helium Markets Renergen Expected to Benefit from $750 million of Committed Debt Funding from the U.S. government's Development Finance Corporation (U.S. DFC) and Other Lenders to Expand Helium Plant Production Capacity Combined Company Expected to Target Cross-Sector Applications in Semiconductors, Quantum Computing, and Clean Energy DALLAS, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) has successfully closed its previously announced acquisition of Renergen Limited, creating a combined company that is focused on the production of critical isotope

    1/7/26 8:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. Announces Receipt of Regulatory Approvals for Acquisition of Renergen Limited

    WASHINGTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that all required regulatory approvals and clearances have been obtained for ASP Isotopes' proposed offer to acquire all of the issued ordinary shares of JSE-listed Renergen Limited ("Renergen"), pursuant to a scheme of arrangement under South African law pursuant to which Renergen shareholders will receive 0.09196 new ASP Isotopes shares for each Renergen share held on the record date (the "Scheme"). Accordingly, a

    12/17/25 9:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on ASP Isotopes with a new price target

    Cantor Fitzgerald initiated coverage of ASP Isotopes with a rating of Overweight and set a new price target of $13.00

    12/4/25 8:40:44 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Canaccord Genuity initiated coverage on ASP Isotopes with a new price target

    Canaccord Genuity initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $4.50

    10/4/24 7:13:36 AM ET
    $ASPI
    Major Chemicals
    Industrials

    H.C. Wainwright initiated coverage on ASP Isotopes with a new price target

    H.C. Wainwright initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $3.25

    12/5/23 7:36:42 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Kiessling Heather sold $463,840 worth of shares (80,000 units at $5.80), decreasing direct ownership by 10% to 732,500 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    12/29/25 9:30:09 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Director Wider Todd was granted 36,548 shares, increasing direct ownership by 5% to 772,247 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    12/22/25 9:03:20 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Director Ryan Robert John Andrew was granted 36,548 shares, increasing direct ownership by 6% to 652,222 units (SEC Form 4)

    4 - ASP Isotopes Inc. (0001921865) (Issuer)

    12/22/25 9:02:21 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Leadership Updates

    Live Leadership Updates

    View All

    Skyline Announces Change in Strategy, New Management and First Acquisition in Critical Minerals Space

    Hong Kong, Nov. 06, 2025 (GLOBE NEWSWIRE) --  -Appoints Paul Mann Executive Chairman to Lead New Strategic Direction for the Company  -Company makes first Acquisition in Critical Minerals Space Hong Kong, November 6, 2025 (GLOBE NEWSWIRE) – Skyline Builders Group Holding Limited (NASDAQ:SKBL), a Cayman Islands exempted company (the "Company"), today announced a number of strategic changes to the Company's leadership, strategy and corporate headquarters. Appointment of Paul Mann as Executive Chairman Effective January 1, 2026, Paul E. Mann will become Executive Chairman of the Company. Mr. Mann has a 25-year career as an investor and entrepreneur. He is currently the Founder and Executiv

    11/6/25 8:15:00 AM ET
    $ASPI
    $SKBL
    Major Chemicals
    Industrials
    Engineering & Construction
    Consumer Discretionary

    Nuclear Power Industry Veteran Ralph Hunter Joins Board of Directors of ASP Isotopes Inc. and Board of Managers of Quantum Leap Energy LLC

    WASHINGTON, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Ralph L. Hunter, Jr. to the board of directors of ASP Isotopes and the board of managers of Quantum Leap Energy LLC. Ralph L. Hunter, Jr. has over thirty years' experience in the nuclear power industry in leadership roles spanning strategy, operations, and innovation, and he brings expertise in nuclear technology development and commercialization, energy systems, and market development. Mr. Hun

    9/8/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Issues Letter to Shareholders

    WASHINGTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today released the following letter to shareholders from its Chairman and CEO, Paul Mann. Dear Fellow Shareholder, The past few months have been exciting and highly rewarding as the Company has brought three isotope enrichment facilities into operation. I am delighted to report that the Company has now shipped the first samples of both Ytterbium-176 and Silicon-28 to customers, a major milestone for the Company that should allo

    9/2/25 7:30:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by ASP Isotopes Inc.

    SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

    11/14/24 3:01:19 PM ET
    $ASPI
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by ASP Isotopes Inc.

    SC 13G/A - ASP Isotopes Inc. (0001921865) (Subject)

    11/7/24 4:15:14 PM ET
    $ASPI
    Major Chemicals
    Industrials

    SEC Form SC 13G filed by ASP Isotopes Inc.

    SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

    11/3/23 4:15:20 PM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    Financials

    Live finance-specific insights

    View All

    ASP Isotopes to Provide Quarterly Business Update Call on November 21, 2025 at 8:30am EST

    WASHINGTON, Nov. 17, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASP Isotopes" or the "Company"), an advanced materials company focused on developing technologies and processes for the production of isotopes for multiple industries, today announced it will hold a quarterly business update conference call and webcast on Friday, November 21, 2025 at 8:30 a.m. (Eastern Time). Conference Call Information To participate in this event, please log on or dial in approximately 5 minutes before the beginning of the call. Webcast Link https://events.q4inc.com/attendee/428149635 Participant Dial-In Details Date: November 21, 2025Time: 8:30 a.m. ESTDial in: USA / International Tol

    11/17/25 4:31:40 PM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. Hosts South African Investors in Advance of Secondary Listing on the Johannesburg Stock Exchange (JSE) and Provides Updates on its Isotope Production Plants

    - ASP Isotopes will host an investor access event on Tuesday, August 26, 2025 at its Pretoria facilities for approximately 30 South African investors. - ASP Isotopes expects to have a secondary listing on the Johannesburg Stock Exchange (JSE) and its common stock is expected to commence trading on the JSE on Wednesday, August 27, 2025. - ASP Isotopes has shipped its first samples of enriched Silicon-28 to a US-based customer and expects to complete the enrichment of the first samples of Ytterbium 176 during August 2025. - ASP Isotopes Management Team will feature on a RedChip Investor call at 4:15 pm EDT on Thursday, August 28, 2025. Ryno Pretorius, CEO of Quantum Leap Energy, and Stefano

    8/26/25 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment

    - IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked and novel tumor antigens for patients in need of new cancer therapies. - IsoBio has closed its initial Series Seed financing round, raising $5 million from ASP Isotopes Inc. (ASPI). - The strategic collaboration contemplates future manufacturing opportunities for PET Labs (ASPI's nuclear medicine subsidiary). - IsoBio plans to leverage the technology and global manufacturing capabilities developed by ASPI to reduce the uncertainty of isotope supply chain/manufacturi

    7/28/25 8:31:17 AM ET
    $ASPI
    $IMNM
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care